TICKERNERD
Menu
RNAZRNAZHealthcare · Biotechnology

RNAZ Stock Forecast: TransCode Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$1.76
−1.12% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 6 Oct 2026 — in the weakest quartile.

Market cap
$29.8M
Ticker Nerd rank
21 / 100
Median analyst target
—
Analysts covering
1
Revenue$0.0
Operating income−$6.2M
Net income−$6.8M
Free cash flow−$5.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.8%
1M
−14.6%
YTD
−74.2%
1Y
−85.6%
From 52W high
−88.4%
From 52W low
+13.9%
$2
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RNAZ stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores TransCode Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
21 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
86
Quality
75
Value
54
Accruals
41
Growth
26
Revisions
25
Issuance
18
Volatility
11
Momentum
4

Size (86): Smaller than most of the companies we track.

Momentum (4): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RNAZ stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RNAZ, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15Jan 26Apr 26Jul 26Oct 26RNAZ

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
16 Apr 2025HC Wainwright & Co.MaintainsBuy$20 → $10
13 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Feb 2025HC Wainwright & Co.ReiteratesBuy—
6 Feb 2025HC Wainwright & Co.ReiteratesBuy—
18 Dec 2024HC Wainwright & Co.MaintainsBuy—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
24 Oct 2024HC Wainwright & Co.ReiteratesBuy—
6 Sept 2024HC Wainwright & Co.ReiteratesBuy—
15 Aug 2024HC Wainwright & Co.ReiteratesBuy—
29 May 2024HC Wainwright & Co.ReiteratesBuy—
16 May 2024HC Wainwright & Co.ReiteratesBuy—
16 Apr 2024HC Wainwright & Co.ReiteratesBuy—
3 Apr 2024HC Wainwright & Co.ReiteratesBuy—
24 Oct 2023HC Wainwright & Co.ReiteratesBuy$3.00
15 Aug 2023HC Wainwright & Co.ReiteratesBuy$12
15 Nov 2022HC Wainwright & Co.MaintainsBuy$10 → $6.00
7 June 2022HC Wainwright & Co.InitiatesBuy$10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RNAZ appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RNAZ vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, TransCode Therapeutics, Inc. returned −85.6% against +17.4% for the S&P 500, dividends included.

RNAZ vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26RNAZS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RNAZ analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

TransCode Therapeutics, Inc. (RNAZ) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 76% of US stocks

Price / sales
—
Price / book
0.0×

Cheaper than 92% of US stocks

EV / EBITDA
−7.4×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−59.3%

Higher than 19% of US stocks

Return on assets
−19.9%

Higher than 19% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

TransCode Therapeutics, Inc. (RNAZ) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • TransCode Therapeutics, Inc. has a market value of $29.8M and an enterprise value of $188.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$42.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$22.6M.

  • Shares outstanding: 950,302.

  • Trailing P/E: 0.0×; forward P/E: −2.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • TransCode Therapeutics, Inc. employs 12 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

RNAZ vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RNAZTransCode Therapeutics, Inc.$29.8M
21
CNTXContext Therapeutics, Inc.$29.6M
26
GRDXGridAI Technologies Corp.$29.5M
19
IGCIGC Pharma, Inc.$28.9M
6
BYSIBeyondSpring, Inc.$28.5M
19
MCRBSeres Therapeutics, Inc.$27.8M
56
ATYRaTyr Pharma, Inc.$27.8M
53

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own TransCode Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RNAZ news & analysis

TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up

PRNewsWire · 28 Sept 2026positive

TransCode Therapeutics reported updated follow-up data from its ongoing Phase 1a clinical trial of TTX-MC138 in heavily pretreated patients with advanced solid tumors. In the 14 efficacy-evaluable patients, 71.4% achieved stable disease, 57.1% had disease control through three months, 36.7% through six months, and three patients remained progression-free at one year, with the primary endpoint met and no dose-limiting toxicities reported. Exploratory blood RNA-sequencing indicated treatment-associated antitumor immune activation and biological features linked to stable disease.

Why it matters — This update strengthens evidence of TTX-MC138's antitumor activity and extended disease stabilization in a difficult-to-treat patient population, which is relevant to RNAZ watchers assessing the drug's clinical progress.

TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology

PRNewsWire · 22 Sept 2026positive

TransCode Therapeutics announced that an Australian patent application was accepted and that the Japan Patent Office issued a Notice of Allowance for technologies supporting its RNA-based therapeutic platform for immuno-oncology. These developments strengthen the company's global intellectual property portfolio.

Why it matters — Newly allowed patents in Australia and Japan could reinforce TransCode's differentiation and protect its RNA platform for targeted cancer therapy in key international markets.

TransCode Therapeutics, Inc. (RNAZ) Discusses Advancing Multi-Platform Oncology Pipeline Targeting Metastatic Cancer Transcript

Seeking Alpha · 17 Sept 2026neutral

TransCode Therapeutics discussed advancing its multi-platform oncology pipeline, which targets metastatic cancer transcript. The discussion appears to be based on a transcript of a company presentation or call.

Why it matters — RNAZ watchers would care because the update outlines the company's progress on its oncology pipeline targeting metastatic cancer.

TransCode Therapeutics Announces Leadership Transition

PRNewsWire · 10 Sept 2026neutral

TransCode Therapeutics announced that Chief Financial Officer Tom Fitzgerald is retiring. John Tattory will assume the role of Interim Chief Financial Officer as the company manages this leadership transition.

Why it matters — A change in the CFO role is a significant leadership transition for the clinical-stage company that RNAZ watchers may want to monitor.

TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis

PRNewsWire · 31 Aug 2026positive

TransCode Therapeutics announced the publication of a peer-reviewed article in Cancers reporting that its lead candidate, TTX-MC138, showed significant survival benefits in a preclinical model of breast cancer bone metastasis, with favorable tolerability and no observed systemic toxicity.

Why it matters — This publication provides preclinical evidence supporting the therapeutic potential of TransCode's lead candidate in a hard-to-treat metastatic setting, which is relevant to the company's pipeline progress.

FAQ

Frequently asked questions about RNAZ stock

Is RNAZ stock a buy right now?

Of the 1 analysts covering TransCode Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TransCode Therapeutics, Inc. 21 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RNAZ?

As at 6 Oct 2026, TransCode Therapeutics, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (86 of 100).

What is the RNAZ stock forecast for 2030?

No analyst covering TransCode Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RNAZ are extrapolating price history, which says nothing about the business.

How has RNAZ stock performed over the past year?

TransCode Therapeutics, Inc. returned -85.6% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does TransCode Therapeutics, Inc. do?

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA-based therapies and immuno-oncology programs for high-risk and advanced cancers.

What is the latest news on RNAZ?

The most recent item we track (PRNewsWire, 28 Sept 2026): "TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up". TransCode Therapeutics reported updated follow-up data from its ongoing Phase 1a clinical trial of TTX-MC138 in heavily pretreated patients with advanced solid tumors. In the 14 efficacy-evaluable patients, 71.4% achieved stable disease, 57.1% had disease control through three months, 36.7% through six months, and three patients remained progression-free at one year, with the primary endpoint met and no dose-limiting toxicities reported. Exploratory blood RNA-sequencing indicated treatment-associated antitumor immune activation and biological features linked to stable disease.

Company

About TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA-based therapies and immuno-oncology programs for high-risk and advanced cancers. The company’s current work centers on targeted cancer therapeutics designed to address metastatic disease, including candidates that modulate microRNA pathways and other genetic mechanisms linked to tumor growth and spread. Its pipeline also includes programs exploring RNA delivery platforms and combination approaches aimed at improving how nucleic-acid medicines reach cancer cells. TransCode Therapeutics operates within the oncology and RNA therapeutics segments of the life sciences market, where it contributes to the development of precision treatments for difficult-to-treat malignancies. Headquartered in Boston, Massachusetts, the company concentrates on advancing experimental cancer therapies through clinical and preclinical development.

CEO Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D. · 12 employees · United States · https://www.transcodetherapeutics.com